11 Best 52-Week Low Stocks to Buy Right Now

Page 10 of 10

1. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Price: $521.00 

52 Week Range: $476.49 – $1,211.20 

Analyst Upside: 43.95%

Number of Hedge Fund Holders: 66

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On June 20, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced that its Dupixent has been approved as the only targeted medicine to treat Bullous Pemphigoid in the United States.

Bullous pemphigoid is a chronic disease characterized by intense itching, painful blisters, skin lesions, and redness. Until now, treatment options for Bullous pemphigoid were limited and often involved suppressing the immune system with oral corticosteroids, which can add to the disease burden, especially in elderly patients.

Dupixent is the first and only targeted medicine approved in the United States addressing two central drivers of type 2 inflammation. The treatment reduces itch, improves disease symptoms, and helps some patients achieve sustained remission while decreasing the need for oral corticosteroids.

The approval for Regeneron Pharmaceuticals, Inc.’s  (NASDAQ:REGN) Dupixent was based on results from the pivotal ADEPT Phase 2/3 clinical trial, which showed 18.3% of Dupixent-treated patients achieved sustained disease remission. Moreover, the regulatory submissions for Dupixent in BP are also under review in other regions, including the EU, Japan, and China.

While we acknowledge the potential of REGN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than REGN and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

Page 10 of 10